ArticleFrontiers in pharmacology2023

Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma.

Yufan Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.